Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kesimpta in Chinese adults with relapsing multiple sclerosis
CTR20220189Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started Feb 2022; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20220189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220189.